fda ban tirzepatide says compounding pharmacies can keep making weight-loss med tirzepatide, for now FDA's tirzepatide decision creates uncertainty

Conclusion We concluded that GLP-1 receptor agonist therapy could reduce the risk of death from cardiovascular causes and fatal or non-fatal stroke compared with the placebo in the treatment of T2DM patients in trials with cardiovascular outcomes

Wound healing and angiogenesis GHK-Cu has been studied extensively in wound healing contexts

For Retatrutide, a common approach is to add 1 mL of bacteriostatic water to a 10 mg vial, making each 0.1 mL (10 units on an insulin syringe) equal to 1 mg

A single documented case (Gordon et al., JAAD Case Reports 2024) showed a measurable improvement in hair density in a 57-year-old man with insulin resistance after twelve months on tirzepatide